1. FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30‐POSITIVE (CD30+) CUTANEOUS T‐CELL LYMPHOMA (CTCL). (12th June 2019) Authors: Horwitz, S.M.; Scarisbrick, J.; Prince, H.M.; Whittaker, S.; Duvic, M.; Kim, Y.H.; Quaglino, P.; Zinzani, P.L.; Bechter, O.; Eradat, H.; Pinter‐Brown, L.; Akilov, O.; Geskin, L.; Sanches, J.; Ortiz‐Romero, P.; Lisano, J.; Brown, L.; Palanca‐Wessels, M.C.; Gautam, A.; Bunn, V. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 286 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. ONGOING PHASE 1B/2 TRIALS OF MOSUNETUZUMAB INVESTIGATING NOVEL TREATMENT REGIMENS FOR PATIENTS WITH B‐CELL NON‐HODGKIN LYMPHOMA (NHL). (12th June 2019) Authors: Budde, L.E.; Vallurupalli, A.; Babu, S.; Lossos, I.S.; Alderuccio, J.P.; Chavez, J.C.; Eradat, H.; Holmes, H.; Hamadani, M.; Karur, V.G.; Olszewski, A.J.; Seymour, E.; Althaus, B.; Medeiros, B.M.; Li, C.C.; Kwan, A.; Wei, M.C.; Yin, S.; O'Hear, C.; Munoz, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 564 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P682: NEMTABRUTINIB (MK-1026), A NON-COVALENT INHIBITOR OF WILD-TYPE AND C481S MUTATED BRUTON TYROSINE KINASE FOR B-CELL MALIGNANCIES: EFFICACY AND SAFETY OF THE PHASE 2 DOSE-EXPANSION BELLWAVE-001 STUDY. (23rd June 2022) Authors: Woyach, J.; Flinn, I. W.; Awan, F. T.; Eradat, H.; Brander, D.; Tees, M.; Parikh, S. A.; Phillips, T.; Wang, W.; Reddy, N. M.; Farooqui, M. Z.; Byrd, J. C.; Stephens, D. M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 578 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. RESPONSE BY STAGE IN CD30‐POSITIVE (CD30+) CUTANEOUS T CELL LYMPHOMA (CTCL) PATIENTS RECEIVING BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN THE PHASE 3 ALCANZA STUDY. (June 2017) Authors: Horwitz, S.; Whittaker, S.; Duvic, M.; Dummer, R.; Kim, Y.H.; Scarisbrick, J.; Quaglino, P.; Zinzani, P.; Wolter, P.; Eradat, H.; Sanches, J.; Ortiz‐Romero, P.; Akilov, O.; Trotman, J.; Taylor, K.; Dalle, S.; Weichenthal, M.; Walewski, J.; Fisher, D.; Wang, Y. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 245 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗